Resminostat

Resminostat (4SC-201 or RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Resminostat (4SC-201 or RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents. In 2011, the German drug maker 4SC was granted orphan drug designation for resminostat by the US FDA for the treatment of hepatocellular carcinoma (HCC). In 2016, the FDA granted IND for clinical tests in combination with sorafenib for HCC.

4SC say "In several phase I and phase II trials, resminostat has already demonstrated very good safety and tolerability, alongside promising indications of efficacy."

Clinical trials

Resminostat has undergone a phase I/II clinical trial for K-ras mutated advanced colorectal carcinoma. It has undergone a phase II clinical trial for relapsed or refractory Hodgkin's lymphoma.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1335528491 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.